Caraco Pharmaceutical Laboratories Ltd
Caraco Pharmaceutical Laboratories — Investor Presentation (November 2006)
22 slides from Caraco Pharmaceutical Laboratories's investor presentation, Nov 14, 2006
Slide 1: Caraco Pharmaceutical Laboratories, Ltd.
Caraco Pharmaceutical Laboratories, Ltd.
Slide 2: Safe Harbor
Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual re
Slide 3: Caraco Overview: What sets us apart from the pack?
Caraco Overview What sets us apart from the pack? Size of our Product Portfolio vs. the Size of Company Experienced Management Team Vertically Integrated via Sun API’s Disciplined Management Ability to Service our Customers’ Immediate Needs Capable of Creating Markets that Previously did not Exist
Slide 4: Overview: What sets us apart from the pack?
Caraco Overview What sets us apart from the pack? Low Cost Production Size Plays to our Advantage Ability to Penetrate the Market Building to fit the Current Environment Improved Customer Mix Removal of Barriers, Execution
Slide 5: Annual Historical Results
Caraco Pharmaceutical Laboratories, LTD Annual Historical Results (in US $ millions) (2) (1) (0) (10) ($10) $0 $10 $20 $30 $40 $50 $60 $70 $80 $90 2002 2003 2004 F2006* Net Sales Gross Profit Net Income Net Cash Income Cash Flow from operations *Change in fiscal year
Slide 6: Quarterly Analysis
20 21 25 25 28 Caraco Pharmaceutical Laboratories, LTD Quarterly Analysis (in US $ millions) (5) (1) (1) (6) ($6) ($1) $4 $9 $14 $19 $24 $29 Q2-F2006 Q3-F2006 Q4-F2006 Q1-F2007 Q2-F2007 Net Sales Gross Profit Net Income Net Cash Income Cash Flow From Operations
Slide 7: Sales for Fiscal 2006
Caraco Pharmaceutical Laboratories, LTD SALES for Fiscal 2006 (in US $ millions) $0 $20 $40 $60 $80 $100 $120 Actual Q1 F2006 Actual Q2 F2006 Actual Q3 F2006 Actual Q4 F2006 Forecast F2006 Actual F2006* Forecast F2007 Net Sales Represents 40% growth over Calendar 2004 Represents 25% growth over Fisc
Slide 8: Product Development Quarterly Filings (ANDAs)
3 5 10 3 6 Caraco Pharmaceutical Laboratories, LTD Product Development Quarterly Filings (ANDAS) Y 2004 QT 2005 Fiscal 2006 YTD Fiscal 2007 2Q-F2007 Number of ANDA Filings ANDAs Awaiting Approval* *Includes two tentative FDA approvals
Slide 9: Product Market Share Trends
Caraco Pharmaceutical Laboratories, LTD Product Market Share Trends Caraco is Currently Marketing 26 Generic Pharmaceuticals and One Brand Product Three of the 26 Products were Launched in the Second Quarter of Fiscal 2007 Eight of the 26 Products are in the Top Three of Generic Market Share Tramado
Slide 10: Net Sales by Trade Class
Caraco Pharmaceutical Laboratories, LTD Net Sales by Trade Class July 2005 - September 2005 Q2-F2006 Chain - 1.27MM Dist - 6.05MM Whole - 2.68MM Mg Care - 2.82MM Govt - 6.95MM July 2006 - September 2006 Q2-F2007 Chain - 3.06MM Dist - 5.81MM Whole - 4.97MM Mg Care - 5.91 Govt - 8.48MM
Slide 11: Net Sales by Trade Class
Caraco Pharmaceutical Laboratories, LTD Net Sales by Trade Class $ in millions July-Sept 2005 (2Q-F2006) July-Sept 2006 (2Q-F2007) Chain Dist Whole Mg Care Govt Growth Percentages Chain : 140.9% Dist : - 4.0% Whole : 85.4% Mg Care : 109.6% Govt : 22.0%
Slide 12: Second Quarter Fiscal 2007 Highlights
Second Quarter Fiscal 2007 Highlights Recognized by One of the Big Three Wholesalers in US as Best Trade Representative for Companies Under $100 Million in Sales with that Wholesaler Acquired Packaging Facility Signed Definitive Agreement with New Product Development Partner
Slide 13: Second Quarter Fiscal 2007 Highlights
Second Quarter Fiscal 2007 Highlights Launched Three Products - Baclofen, Meloxicam and Glipizide Filed Three Products with FDA Bringing Total Products Awaiting Approval to 17 Including Two Tentative Approvals Continued Profitability (with stock transfer for two products versus 1 last quarter) Recor
Slide 14: Second Quarter Fiscal 2007 Highlights
Second Quarter Fiscal 2007 Highlights Second Quarter Net Sales Growth of 43% Year-over-Year (YTD 42%) Gross Profit 50% Successive Quarterly Growth of 14%
Slide 15: Expansion
Expansion Current facility is 80,000 sq ft and lease another 62,000 sq ft for total footprint of 142,000 sq ft Need to build 80,000 - 100,000 sq ft facility or move to 250,000 sq. ft cGMP facility for complete company move Fiscal 2007 forecast is for an average of 263 million tablets per month. Need
Slide 16: Accomplishments Fiscal 2006
Accomplishments Fiscal 2006 Increased Training in cGMP Award of Top 500 Fastest Growing Technology Companies Ranked 96th by Deloitte & Touche Award of Future 50 Representing the top 50 Growth Companies in Metro Detroit Based on Sales and Employment
Slide 17: Accomplishments Fiscal 2006
Accomplishments Fiscal 2006 Filed 10 Products with the FDA in Fiscal 2006 Surpassed our Net Sales Forecast for 2006 by Almost $3 Million Increased Manufacturing Capacity by 35% Maintained Gross Profit of 49% which is Above the Generic Industry Average Developed Clozapine Registry Web site for Electr
Slide 18: Clozapine Sales Update & Web Registry Development
Caraco Pharmaceutical Laboratories, LTD Clozapine Sales Update & Web Registry Development Caraco successfully launched www.caracoclozapine.com on March 20 th 2006 New confirmed customer commitments Distributor Class of Trade Large distributor buying group Large managed care (HMO) player Two of Big T
Slide 19: Product Litigation
Product Litigation Lexapro – Teva Lost Infringement Case and is Set to Appeal; Possible Upside if Caraco Prevails Prandin – First to File Position Provigil – Determine Next Steps to Monetize Ultracet – Ortho Filed Suit Based on New Patent Effective August 1st which we Certified we do not Infringe; O
Slide 20: Drivers Fiscal 2007
Drivers Fiscal 2007 Approvals - Baclofen, Meloxicam, Glipizide, Full-Year Tramadol with Acetaminophen Approvals Pending Increase / Maintain Share Increase and Close Alternate Development Projects
Slide 21: Drivers Fiscal 2007
Drivers Fiscal 2007 Expand Current Development Streams and Pursue New Opportunities Expansion of Current Facilities Improve Packaging Continue Staff Improvements and Succession Planning
Slide 22: Thank You
CARACO Thank You
Caraco Pharmaceutical Laboratories — Investor Presentation (November 2006) on 6ix